Visit the ALS News Today forums to connect with others in the ALS community. View Forums. More news. Click the link below to find all the latest news related to ALS. Read more. Perspectives. Go to previous slide Go to next slide. March 6, 2025 Columns by Kristin Neva.

New analyses in ALS planned to aid CNM-Au8’s accelerated approval. Clene is collaborating with APST Research to further explore how CNM-Au8 affects levels of neurofilament light chain (NfL) among amyotrophic lateral sclerosis (ALS) patients being treated in expanded access programs (EAPs). The joint effort is intended to support the ...

Jan 27, 2025 · The new data were presented at the ALS Network Research Summit, held earlier this month in San Francisco, by Michael McGrath, MD, PhD, Neuvivo’s founder and chief scientific officer. Ari Azhir, PhD, CEO and also a founder of Neuvivo, noted that the new findings “align well” with the other data published last fall, and “add to the body ...

Feb 18, 2025 · The ALS Association, a U.S.-based nonprofit whose mission is to help find a cure for amyotrophic lateral sclerosis (ALS), has issued a statement strongly opposing plans for cuts in National Institutes of Health (NIH) funding, saying any such reductions would obstruct progress in ALS research. The ...

Jan 13, 2025 · Antibodies seen as new treatments for ALS. Alchemab said it has hundreds of ALS samples. It will use samples from people with unusually slow disease progression to look for antibodies that may be conferring protection to patients, the idea being that these antibodies could serve as the basis for new treatments.

Jan 21, 2025 · All seven had slowly progressing ALS, defined by a decline in ALS Functional Rating Scale-Revised (ALSFRS-R) score of fewer than 0.9 points per month. Patients were losing 0.36 ALSFRS-R points each month on average. Patients had been living with ALS for 62.7 months, or just over five years, before starting Qalsody. Their mean ALSFRS-R score was ...

Jun 8, 2023 · A Phase 3 clinical trial (NCT03280056), completed in 2020, had tested NurOwn in patients with rapidly progressing ALS, who were given three injections of either the therapy or a placebo two months apart.The trial involved 189 adults followed for 28 weeks, or about seven months. The results showed that NurOwn was not significantly more effective than a placebo …

Sep 6, 2024 · Studies in ALS animal models showed it also may help treat cachexia and disease-related muscle wasting in people with ALS. ALS is a devastating orphan disease of high, unmet medical need and the early non-clinical data we have generated for S-oxprenolol in this indication suggest that it could play a role in addressing some of the key needs of ...

Jan 6, 2025 · The trial (NCT06556394) aims to determine the safety and tolerability, pharmacological properties, and preliminary signs of efficacy of multiple dose levels of RAG-17.. It will enroll about 32 people with SOD1-ALS who will be randomly assigned to receive the experimental RNA-based therapy or a placebo via an injection into the spinal canal.

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by the progressive loss of motor neurons, nerve cells that control the voluntary muscles. This leads to symptoms that include overall muscle weakness, causing difficulties with moving, breathing, eating, and speaking. There are a number of experimental treatments in the pipeline for the …